On Friday, Actavis plc (NYSE:ACT)’s shares inclined 1.92% to $292.82.
Actavis plc (ACT) declared that it will right away re-launch its generic version of AstraZeneca’s Pulmicort RESPULES® 0.25 and 0.5 mg vials following a decision from the United States Court of Appeals for the Federal Circuit to uphold a lower court’s ruling that United States Patent No. 7,524,834 is invalid. The Appeals court also dissolved the injunction preventing Actavis from further distribution of its generic version of Pulmicort RESPULES® that was granted on March 12, 2015.
Actavis plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic, branded generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. It operates in three segments: North American Brands, North American Generics and International, and Anda Distribution.
Orexigen Therapeutics, Inc. (NASDAQ:OREX)’s shares gained 4.41% to $6.87.
Orexigen Therapeutics, Inc. (OREX) declared that administration will present a corporate overview at the 2015 Bank of America Merrill Lynch Health Care Conference in Las Vegas. The presentation is planned for Tuesday, May 12th at 1 p.m. Pacific Time. To listen to the live webcast or a replay of the talk about, please visit the Investors section of the Company’s Web site at www.orexigen.com. A replay will be accessible for 14 days after the event.
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products in the United States. The company offers Contrave for the treatment of obesity.
At the end of Friday’s trade, Medivation Inc (NASDAQ:MDVN)‘s shares surged 0.34% to $123.65.
Medivation Inc (MDVN) stated its financial results for the first quarter ended March 31, 2015. U.S. net sales of XTANDI® capsules, as stated by Astellas Pharma Inc., were $224.0 million for the quarter (+80% vs. preceding year). On its February 25, 2015 earnings call, Medivation stated its expectation that first quarter U.S. net sales may be at or below fourth quarter 2014 net sales of $230.2 million. First quarter U.S. net sales of $224.0 million were driven by an enhance in underlying demand (low teens percent) offset by an anticipated higher gross-to-net rate as contrast with fourth quarter net sales of $230.2 million, which comprised of an enhance in channel partner inventory of about one week.
Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients.
StemCells Inc (NASDAQ:STEM), ended its Friday’s trading session with -2.82% loss, and closed at $0.620.
StemCells Inc (STEM) offered a business update and stated financial results for the first quarter 2015.
First Quarter 2015 and Recent Highlights
In February 2015, Theodore Leng, MD, MS, Clinical Assistant Professor of Ophthalmology at the Byers Eye Institute at Stanford, Stanford University School of Medicine, and a principal investigator on StemCells, Inc.’s Phase I/II study in dry age related macular degeneration, presented findings on the safety and preliminary efficacy of our proprietary HuCNS-SC(R) human neural stem cells for dry age related macular degeneration (AMD) at the Angiogenesis, Exudation and Degeneration 2015 symposium.
In March 2015, Ian Massey, D. Phil., joined the Company’s executive team as President and Chief Operating Officer. In this new role, Dr. Massey has direct responsibility for all aspects of the Company’s research and development, manufacturing, regulatory affairs, and quality assurance activities. He reports to Martin McGlynn, the Company’s Chief Executive Officer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
